Related Experiment Video
Updated: Dec 25, 2025
Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks
Published on: November 10, 2016
XPA: DNA Repair Protein of Significant Clinical Importance
Lucia Borszéková Pulzová1, Thomas A Ward2, Miroslav Chovanec1
1Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy Sciences, 845 05 Bratislava, Slovak Republic.
Abstract:
The nucleotide excision repair (NER) pathway is activated in response to a broad spectrum of DNA lesions, including bulky lesions induced by platinum-based chemotherapeutic agents. Expression levels of NER factors and resistance to chemotherapy has been examined with some suggestion that NER plays a role in tumour resistance; however, there is a great degree of variability in these studies. Nevertheless, recent clinical studies have suggested Xeroderma Pigmentosum group A (XPA) protein, a key regulator of the NER pathway that is essential for the repair of DNA damage induced by platinum-based chemotherapeutics, as a potential prognostic and predictive biomarker for response to treatment. XPA functions in damage verification step in NER, as well as a molecular scaffold to assemble other NER core factors around the DNA damage site, mediated by protein-protein interactions. In this review, we focus on the interacting partners and mechanisms of regulation of the XPA protein. We summarize clinical oncology data related to this DNA repair factor, particularly its relationship with treatment outcome, and examine the potential of XPA as a target for small molecule inhibitors.
Insights
The Xeroderma Pigmentosum group A (XPA) protein is crucial for DNA repair and platinum-based chemotherapy. XPA shows potential as a biomarker for predicting treatment response and as a therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- DNA Repair
Background:
- The nucleotide excision repair (NER) pathway repairs DNA damage from chemotherapy.
- NER factor expression and cancer treatment resistance show variable correlations.
- Xeroderma Pigmentosum group A (XPA) protein is a key NER regulator.
Purpose of the Study:
- To review the interacting partners and regulatory mechanisms of XPA protein.
- To summarize clinical oncology data on XPA and its relation to treatment outcomes.
- To examine the potential of XPA as a target for small molecule inhibitors.
Main Methods:
- Literature review of XPA protein interactions and regulation.
- Analysis of clinical oncology studies on XPA and treatment response.
- Exploration of XPA as a therapeutic target.
Main Results:
- XPA protein is essential for DNA damage verification and assembling NER factors.
- Clinical studies suggest XPA is a potential prognostic and predictive biomarker for platinum-based chemotherapy.
- XPA's role in tumor resistance and its potential as a drug target are highlighted.
Conclusions:
- XPA protein is a critical component of the NER pathway, vital for repairing DNA damage induced by platinum chemotherapeutics.
- XPA holds significant promise as a biomarker for predicting patient response to chemotherapy and as a target for novel cancer therapies.
Related Concept Videos
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair
01:02Long-patch Base Excision Repair
02:36DNA Damage can Stall the Cell Cycle
02:36DNA Damage Can Stall the Cell Cycle
02:25Overview of DNA Repair
Chemically...